key: cord-0753802-zrbucw8x
authors: García‐Lamberechts, Eric Jorge; Miró, Òscar; Fragiel, Marcos; Llorens, Pere; Jiménez, Sònia; Piñera, Pascual; Burillo‐Putze, Guillermo; Martín, Alfonso; Martín‐Sánchez, Francisco Javier; Jacob, Javier; Alquézar‐Arbé, Aitor; Ejarque Martínez, Laura; Rodríguez Miranda, Belén; Ruiz Grinspan, Martín; Domínguez, María Jesús; Teigell Muñoz, Francisco Javier; Gayoso Martín, Sara; García García, Ángel; Iglesias Vela, Marta; Carbajosa, Virginia; Salido Mota, Manuel; Marchena González, María José; Agüera Urbano, Carmen; Porta‐Etessam, Jesus; Calvo, Elpidio; González del Castillo, Juan
title: A case‐control analysis of stroke in COVID‐19 patients: Results of unusual manifestations of COVID‐19–study 11
date: 2021-09-29
journal: Acad Emerg Med
DOI: 10.1111/acem.14389
sha: 5f3feb44f3b365e16671659866d4d6b8251a7131
doc_id: 753802
cord_uid: zrbucw8x

OBJECTIVE: We investigated the incidence, predictor variables, clinical characteristics, and stroke outcomes in patients with COVID‐19 seen in emergency departments (EDs) before hospitalization. METHODS: We retrospectively reviewed all COVID‐19 patients diagnosed with stroke during the COVID‐19 outbreak in 62 Spanish EDs. We formed two control groups: COVID‐19 patients without stroke (control A) and non–COVID‐19 patients with stroke (control B). We compared disease characteristics and four outcomes between cases and controls. RESULTS: We identified 147 strokes in 74,814 patients with COVID‐19 seen in EDs (1.96‰, 95% confidence interval [CI] = 1.66‰ to 2.31‰), being lower than in non–COVID‐19 patients (6,541/1,388,879, 4.71‰, 95% CI = 4.60‰ to 4.83‰; odds ratio [OR] = 0.42, 95% CI = 0.35 to 0.49). The estimated that standardized incidences of stroke per 100,000 individuals per year were 124 and 133 for COVID‐19 and non–COVID‐19 individuals, respectively (OR = 0.93 for COVID patients, 95% CI = 0.87 to 0.99). Baseline characteristics associated with a higher risk of stroke in COVID‐19 patients were hypertension, diabetes mellitus, and previous cerebrovascular and coronary diseases. Clinically, these patients more frequently presented with confusion, decreased consciousness, and syncope and higher D‐dimer concentrations and leukocyte count at ED arrival. After adjustment for age and sex, the case group had higher hospitalization and intensive care unit (ICU) admission rates (but not mortality) than COVID‐19 controls without stroke (OR = 3.41, 95% CI = 1.27 to 9.16; and OR = 3.79, 95% CI = 1.69 to 8.50, respectively) and longer hospitalization and greater in‐hospital mortality than stroke controls without COVID‐19 (OR = 1.55, 95% CI = 1.24 to 1.94; and OR = 1.77, 95% CI = 1.37 to 2.30, respectively). CONCLUSIONS: The incidence of stroke in COVID‐19 patients presenting to EDs was lower than that in the non–COVID‐19 reference sample. COVID‐19 patients with stroke had greater need for hospitalization and ICU admission than those without stroke and longer hospitalization and greater in‐hospital mortality than non–COVID‐19 patients with stroke.

COVID-19 patients, 7 and according to this higher incidence of severe COVID-19, close monitoring of this subset of patients in the intensive care unit (ICU) care has been suggested. 8 In addition to predisposing baseline risk factors, other potential mechanisms leading to an increased risk of stroke in COVID-19 patients have been reported and include the hypercoagulability state present in some COVID-19 patients. 1 Some of them are the increase of systemic inflammation with a cytokine storm, 9 prolonged immobilization of COVID-19 patients favoring blood stasis and thrombosis, the development of cardioembolism from virus-related cardiac injury, 10 and direct viral invasion of the nervous system that has been associated with hemorrhagic necrotizing encephalopathy. 11 Nevertheless, the real incidence of stroke in patients with COVID-19 is currently unknown, and the risk factors associated with stroke development are unclear. Bearing in mind all these uncertainties, we planned the current study, with the following specific objectives: (1) to determine the frequency of stroke in patients with COVID-19, (2) to uncover the predictor variables associated with the development of stroke in patients with (3) to describe whether there is any distinctive clinical characteristics in these patients in comparison with stroke observed in non-COVID-19 patients, and (4) to investigate the outcomes of COVID-19 patients presenting stroke.

This was a retrospective, case-control, multicenter study that reviewed the medical reports of COVID-19 patients presenting to a Spanish emergency department (ED) diagnosed with stroke during ED assessment and management before hospitalization. In Spain, the first case of SARS-CoV-2 infection was detected on January 31, 2020, and, accordingly, the definition of the COVID-19 period for patient inclusion in this study was set from March 1 to April 30, 2020 . During this 61-day period, 213,435 cases of COVID-19 were confirmed in Spain by the Ministry of Health. 12 This study forms part of the Unusual Manifestations of Covid-19 project, which was designed to investigate the potential relationship between COVID-19 and 10 different entities that could be influenced by SARS-CoV-2 infection: spontaneous pneumothorax, acute pancreatitis, meningoencephalitis, Guillain-Barre syndrome, myopericarditis, acute coronary syndrome, deep venous thrombosis, pulmonary embolism, stroke, and gastrointestinal bleeding. [13] [14] [15] [16] [17] [18] [19] [20] [21] The main objectives of the UMC-19 project were common for all entities and consisted of the description of incidence, predictor variables, clinical characteristics and outcomes for each particular entity, using as comparators COVID-19 patients who did not develop the entity as well as non-COVID-19 patients who did present the entity.

The investigators of the UMC-19 project initially contacted 152 Spanish EDs, which roughly constitute half of the 312 hospital EDs of the Spanish public health network. Eighty-one of these EDs reported interest in participating and analyzed the protocol, and finally 62 agreed to participate and contributed the required data ( Figure 1 ). These 62 hospitals serve a population of 15.5 million (33% of the overall Spanish population of 46.9 million) and are a quite balanced representation of the Spanish territory (12 of the 17 Spanish autonomous communities were represented), type of hospital (community, reference, and high-technology university hospitals were included), and involvement in the pandemic. 6 The investigation of stroke in COVID-19 patients, one of the entities included in the UMC-19 project, was labeled as the UMC-19 Study 11 (UMC-19-S 11 ) and consisted of a retrospective, casecontrol, ED-based, multicenter study that reviewed the medical reports of COVID-19 patients diagnosed with stroke during ED assessment and management in Spanish EDs before hospitalization.

The case group was formed by COVID-19 patients with a diagnosis of stroke based on clinical and radiologic findings. All strokes were confirmed by a neurologist. Patients in whom stroke were diagnosed during hospitalization but not during ED patient care were excluded. Diagnosis of COVID-19 was accepted based on SARS-CoV-2 detection in nasopharyngeal swab by reverse transcriptasepolymerase chain reaction (RT-PCR) and a clinically compatible picture (including at least malaise, fever, and cough) with the presence of the typical lung parenchymal infiltrates in chest X-ray or pulmonary CT in patients with some other clinical symptoms attributable to COVID-19.

We defined two different control groups. One group was formed by COVID-19 patients (without stroke) presenting to the ED during the same period of the COVID-19 outbreak as that used for case inclusion (March 1 to April 30, 2020). This group was formed by selecting two nonstroke COVID-19-positive patients for every COVID-19 stroke case. They were the COVID-19 patients seen immediately before and after the COVID-positive stroke case (case:control ratio of 1:2). This group, named control group A (COVID-19 controls without stroke), was specifically designed to uncover the predictor variables for stroke development in COVID-19 patients.

The other control group was formed by non-COVID-19 patients diagnosed with stroke seen in the ED during the same period as the cases (March 1 to April 30, 2020), which was defined in the same terms as the cases. To avoid some of these control cases eventually having inadvertent infection by SARS-CoV-2, in this group we also included all patients with stroke diagnosed in the ED from March 1 to April 30, 2019, just 1 year before the COVID-19 pandemic. From the complete list of stroke diagnoses performed in the ED during this 4-month period, we randomly selected two non-COVID-19 patients with stroke for every case (case:control ratio of 1:2). This group, named control group B (stroke controls without COVID- 19) , was specifically designed to uncover the particular distinctive clinical characteristics of stroke developed in COVID-19 patients with respect to stroke developed in the general population.

We collected 59 independent variables from the medical reports, which included two demographic data (age, sex), 12 comorbidities (hypertension, dyslipidemia, diabetes mellitus, coronary artery disease, obesity clinically estimated, chronic obstructive pulmonary disease, asthma, active smoker, cerebrovascular disease, chronic kidney disease creatinine > 2 mg/dL, dementia, active cancer), 18 symptoms (time elapsed since symptoms started to ED attendance, fever, rhinorrhea, cough, expectoration, dyspnea, chest pain, syncope, hemoptysis, abdominal pain, vomiting, diarrhea, confusion, low level of consciousness, headache, anosmia, dysgeusia, symptoms associated with a stroke diagnosis upon initial presentation such as focal neurologic deficit), five vitals at ED arrival (temperature, systolic blood pressure [SBP], heart rate, respiratory rate, room air pulse oximetry), 16 laboratory parameters (C-reactive protein

[CRP], creatinine, sodium, potassium, aspartate aminotransferase

[AST], bilirubin, lactate dehydrogenase [LDH], procalcitonin, ferritin, hemoglobin, leukocytes, platelets, D-dimer, prothrombin time, activated partial thromboplastin time), four radiologic findings in chest X-ray (cardiomegaly, lung interstitial infiltrates, ground-glass opacities, pleural effusion), and two electrocardiogram (ECG) data (rhythm and corrected QT interval). In addition, for cases and control B patients (stroke controls without COVID-19), data from a brain computerized tomography (CT) study was also recorded.

We defined four different outcomes for cases and controls. They consisted of: (1) the need for hospitalization; (2) the need for admission to an ICU; (3) prolonged hospitalization (defined as length of hospitalization greater than 7 days, which is the median length of stay in Spanish hospitals [for the latter, time was dichotomized to detect prolonged hospitalization, that was defined as a length of stay longer than 7 days from the ED arrival to patient discharge home];

and (4) in-hospital all-cause mortality.

Taking into account the epidemiologic context of the 2 months of the study period, we considered that exclusive analysis of patients 

We performed a retrospective study that was performed as part of a larger COVID-19 study and, as such, no specific sample size was calculated for the specific outcomes and statistical analysis of this exploratory stroke study. Differences between the case group and controls groups were assessed by the chi-square test (or Fisher exact test if needed) for qualitative variables and the Mann-Whitney nonparametric test for quantitative variables. The magnitude of associations was expressed as unadjusted odds ratio (OR) with 95% CI, and for these estimations the continuous variables were dichotomized using clinically meaningful cutoffs. Because the number of cases expected to be identified was not large, we did not plan to go further in the investigation of the significant relationships identified in the unadjusted analysis using adjusted models. The only exception was the estimation of outcomes, which were adjusted for age and sex. Finally, we performed some sensitivity analyses of outcomes: (1) 

The UMC-19 project was approved by the ethics committee of the Hospital Clínic of Barcelona (Spain) that acted as the central TA B L E 1 Baseline characteristics of patients with COVID-19 with stroke and comparison with patients with COVID-19 without stroke (control group A) and with patients with stroke without COVID-19 (control group B) Table 4 When cases were compared with controls, some statistically significant differences were found (Tables 1 and 2 ). The magnitudes of these associations are shown in Figure 2 ). Sensitivity analyses of outcomes supported all these results (Table 4) .

We found that around 2‰ of COVID-19 patients coming to the ED presented with stroke. This frequency, found during a 2-month period of the COVID-19 outbreak, should be considered as high, but it is lower than the incidence in non-COVID-19 patients (4.71‰ ED comers). The reported global crude incidence of stroke in the population ranges from 234 to 284 per 100,000 person-years, but varies greatly between countries, and stroke incidence rates in high-income countries are usually lower than in middle-low income countries. 23 In sons/year). 24 Differences with our incidence could be partly related to the time elapsed (15 years) between the previous data and that found in our study, and to the fact that during the COVID-19 pandemic, many countries reported a sharp reduction in admissions of patients with stroke, suggesting that patients with mild symptoms TA B L E 4 Sensitivity analysis for outcomes (adjusted for age and sex) in COVID patients with stroke (case group) compared with COVID-19 controls without stroke (control group A) and stroke controls without COVID-19 (control group B) were not referred to hospital [25] [26] [27] or they spontaneously preferred to stay home and not contact medical assistance during population lockdown due to fear of COVID-19 contagion. 28 In our study, COVID-19 patients with stroke had higher percentages of hospitalization, ICU admission, prolonged stay, and in-hospital mortality than control groups A and B. However, after adjustment for age and sex, the case group only maintained significantly higher rates for hospitalization and ICU admission than control group A (COVID-19 controls without stroke) and for prolonged hospitalization and in-hospital mortality than control group B (stroke controls without COVID-19). This means that age seems to generate some confusion in the interpretation of outcomes, because the cases were older than patients of either of the control groups. This is in contrast with a recent meta-analysis that concluded that previous cerebrovascular and cardiovascular diseases were associated with increased poor outcomes in COVID-19, but this association was not influenced by gender, age, hypertension, diabetes, and respiratory comorbidities. 7 patients developing stroke, the sample size is quite limited and, accordingly, a type II error could be present in some of our estimations.

Despite these limitations, we conclude that in our sample the incidence of stroke in COVID-19 patients presenting to EDs was lower than that of the non-COVID-19 population. COVID-19 patients with focal neurologic deficit, low level of consciousness, confusion, or syncope should be assessed to rule out stroke, particularly in those who have concomitant cardiovascular comorbidities. In our sample, stroke in COVID-19 patients was associated with a higher in-hospital mortality than that of the general non-COVID-19 population.

The authors have no potential conflicts to disclose.

All authors discussed the idea and design of study and provided 

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

Inpatient and outpatient infection as a trigger of cardiovascular disease: the ARIC study

Potential effects of coronaviruses on the cardiovascular system: a review

Influenzalike illness as a trigger for ischemic stroke

Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -a systematic review, meta-analysis, and meta-regression

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19 -systematic review, meta-analysis, and metaregression

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

COVID-19: consider cytokine storm syndromes and immunosuppression

COVID-19 and the heart

COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features

COVID-19: geographical distribution. Ministry of Health. Spanish Government

Incidence, clinical, risk factors and outcomes of Guillain-Barré in Covid-19

Incidence, clinical characteristics, risk factors and outcomes of meningoencephalitis in patients with COVID-19

Analysis of clinical characteristics and outcomes in patients with COVID-19 based on a series of 1000 patients treated in Spanish emergency departments

clinical characteristics, risk factors, and outcomes of upper gastrointestinal bleeding in patients with COVID-19: results of the UMC-19-S12

Incidence, risk factors, clinical characteristics and outcomes of deep venous thrombosis in patients with COVID-19 attending the emergency department: results of the UMC-19-S8

Frequency, risk factors, clinical characteristics, and outcomes of spontaneous pneumothorax in patients with coronavirus disease 2019: a case-control, emergency medicine-based multicenter study

Frequency of five unusual presentations in patients with COVID-19: results of the UMC-19-S (1)

Frequency of five cardiovascular/ hemostatic entities as primary manifestations of SARS-CoV-2 infection: results of the UMC-19-S (2)

A case-control emergency department-based analysis of acute pancreatitis in Covid-19: results of the UMC-19-S (6)

Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, populationbased seroepidemiological study

Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review

Estimation of the prevalence, incidence, comorbidities and direct costs associated to stroke patients requiring care in an area of the Spanish population

COVID-19 and stroke-A global World Stroke Organization perspective

Stroke care in Galicia: telemedicine in the early, multidisciplinary treatment of all acute stroke cases

Factors associated with the activation of emergency medical services in patients with acute stroke: a prospective study

Risk of influenza transmission in a hospital emergency department during the week of highest incidence

Acute stroke care is at risk in the era of COVID-19: experience at a comprehensive stroke center in Barcelona

Large-vessel stroke as a presenting feature of Covid-19 in the young

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Thromboinflammation and the hypercoagulability of COVID-19

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study

Hypertension prevalence and stroke mortality across populations

Risk factors for stroke in the Chinese population: a systematic review and meta-analysis

Atrial fibrillation as an independent risk factor for stroke: the Framingham study

Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the

NIH Stroke Scale reliability in ratings from a large sample of clinicians

Clinical characteristics of coronavirus disease 2019 in China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review

Falling stroke rates during COVID-19 pandemic at a comprehensive stroke center: cover title: falling stroke rates during COVID-19

Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke: the Global COVID-19 Stroke Registry

Acute ischemic stroke and COVID-19: an analysis of 27 676 patients

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Additional supporting information may be found in the online version of the article at the publisher's website. How to cite this article: García-Lamberechts EJ

SIESTA) network. A case-control analysis of stroke in COVID-19 patients: Results of unusual manifestations of COVID-19-study 11

Pascual Piñera Salmerón (Hospital General Universitario Reina Sofía, Murcia), E. Jorge García Lamberechts (Hospital Clínico

Hospital Lluis Alcanys de Xativa: Carles Pérez García

Irene Cabello-Zamora, Alejandro Roset-Rigat. 21. Hospital Universitari Germans Trias i Pujol de

Hospital Universitari de Girona Dr

Hospital de Sant Pau i Santa Tecla (Tarragona): Brigitte Silvana Alarcón Jiménez

Arturo Huerta García. 29. Hospital Clínico San Carlos (Madrid): Marcos Fragiel. 30. Hospital Universitario La Paz (Madrid): Alejandro Martín Quiros

Alejandra Sánchez Arias

Hospital Universitario Regional de Málaga

Hospital Álvaro Cunqueiro

Beatriz María Martínez Bautista. 58. Hospital Universitario de Cabueñes (Gijón): Ana Patricia Niembro Valdes